{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:28:27Z","timestamp":1782937707070,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41375-025-02749-6","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:28:54Z","timestamp":1756808934000},"page":"2640-2651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1\u03b1"],"prefix":"10.1038","volume":"39","author":[{"given":"Guilin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Churan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peitao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-6308","authenticated-orcid":false,"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2749_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146\u201362.","journal-title":"Lancet"},{"key":"2749_CR2","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra2113347","volume":"386","author":"R Fo\u00e0","year":"2022","unstructured":"Fo\u00e0 R, Chiaretti S. Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl J Med. 2022;386:2399\u2013411.","journal-title":"N. Engl J Med"},{"key":"2749_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/306239a0","volume":"306","author":"N Heisterkamp","year":"1983","unstructured":"Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306:239\u201342.","journal-title":"Nature"},{"key":"2749_CR4","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O\u2019Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070\u20137.","journal-title":"Blood"},{"key":"2749_CR5","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. Jama. 2024;331:1814\u201323.","journal-title":"Jama"},{"key":"2749_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajh.24653","volume":"92","author":"S Fujisawa","year":"2017","unstructured":"Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, et al. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol. 2017;92:367\u201374.","journal-title":"Am J Hematol"},{"key":"2749_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023;98:493\u2013501.","journal-title":"Am J Hematol"},{"key":"2749_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945\u201355.","journal-title":"J Clin Oncol"},{"key":"2749_CR9","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","volume":"36","author":"WB Slayton","year":"2018","unstructured":"Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of children\u2019s oncology group trial AALL0622. J Clin Oncol. 2018;36:2306\u201314.","journal-title":"J Clin Oncol"},{"key":"2749_CR10","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/S2352-3026(22)00371-4","volume":"10","author":"S Gupta","year":"2023","unstructured":"Gupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, et al. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children\u2019s Oncology Group cohort trials. Lancet Haematol. 2023;10:e129\u2013e41.","journal-title":"Lancet Haematol"},{"key":"2749_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","volume":"13","author":"A Biondi","year":"2012","unstructured":"Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13:936\u201345.","journal-title":"Lancet Oncol"},{"key":"2749_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"H Pfeifer","year":"2007","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727\u201334.","journal-title":"Blood"},{"key":"2749_CR13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2012.5","volume":"26","author":"H Pfeifer","year":"2012","unstructured":"Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia. 2012;26:1475\u201381.","journal-title":"Leukemia"},{"key":"2749_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"2749_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693\u2013705.","journal-title":"Cell"},{"key":"2749_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41580-018-0081-3","volume":"20","author":"T Narita","year":"2019","unstructured":"Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20:156\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2749_CR17","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/leu.2017.130","volume":"31","author":"J Long","year":"2017","unstructured":"Long J, Fang WY, Chang L, Gao WH, Shen Y, Jia MY, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017;31:2761\u201370.","journal-title":"Leukemia"},{"key":"2749_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","volume":"30","author":"B Dai","year":"2023","unstructured":"Dai B, Wang F, Wang Y, Zhu J, Li Y, Zhang T, et al. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RAR\u03b1. Cell Death Differ. 2023;30:1320\u201333.","journal-title":"Cell Death Differ"},{"key":"2749_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.stem.2015.08.004","volume":"17","author":"J Qi","year":"2015","unstructured":"Qi J, Singh S, Hua WK, Cai Q, Chao SW, Li L, et al. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. Cell Stem Cell. 2015;17:597\u2013610.","journal-title":"Cell Stem Cell"},{"key":"2749_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","volume":"3","author":"G Garcia-Manero","year":"2019","unstructured":"Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019;3:508\u201318.","journal-title":"Blood Adv"},{"key":"2749_CR21","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137:2161\u201370.","journal-title":"Blood"},{"key":"2749_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","volume":"112","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112:981\u20139.","journal-title":"Blood"},{"key":"2749_CR23","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood.2019003538","volume":"135","author":"J Long","year":"2020","unstructured":"Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2020;135:1472\u201383.","journal-title":"Blood"},{"key":"2749_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399\u2013408.","journal-title":"Cell"},{"key":"2749_CR25","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022112675","volume":"42","author":"K Hu","year":"2023","unstructured":"Hu K, Ding Y, Zhu H, Jing X, He W, Yu H, et al. Glutamate dehydrogenase1 supports HIF-1\u03b1 stability to promote colorectal tumorigenesis under hypoxia. Embo j. 2023;42:e112675.","journal-title":"Embo j"},{"key":"2749_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01975-3","volume":"23","author":"F Luo","year":"2024","unstructured":"Luo F, Zhang M, Sun B, Xu C, Yang Y, Zhang Y, et al. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1\/PLK3\/HIF1\u03b1 signaling. Mol Cancer. 2024;23:60.","journal-title":"Mol Cancer"},{"key":"2749_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","volume":"14","author":"XC Ding","year":"2021","unstructured":"Ding XC, Wang LL, Zhang XD, Xu JL, Li PF, Liang H, et al. The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia. J Hematol Oncol. 2021;14:92.","journal-title":"J Hematol Oncol"},{"key":"2749_CR28","doi-asserted-by":"crossref","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132:e159839.","DOI":"10.1172\/JCI159839"},{"key":"2749_CR29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468\u201372.","journal-title":"Science"},{"key":"2749_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.biochem.74.082803.133142","volume":"74","author":"WG Kaelin","year":"2005","unstructured":"Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem. 2005;74:115\u201328.","journal-title":"Annu Rev Biochem"},{"key":"2749_CR31","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/jbmr.2787","volume":"31","author":"ZR Schoepflin","year":"2016","unstructured":"Schoepflin ZR, Shapiro IM, Risbud MV. Class I and IIa HDACs Mediate HIF-1\u03b1 Stability Through PHD2-Dependent Mechanism, While HDAC6, a Class IIb Member, Promotes HIF-1\u03b1 transcriptional activity in nucleus pulposus cells of the intervertebral disc. J Bone Min Res. 2016;31:1287\u201399.","journal-title":"J Bone Min Res"},{"key":"2749_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/cancers15041123","volume":"15","author":"JY Kim","year":"2023","unstructured":"Kim JY, Cho H, Yoo J, Kim GW, Jeon YH, Lee SW, et al. HDAC8 Deacetylates HIF-1\u03b1 and Enhances Its Protein Stability to Promote Tumor Growth and Migration in Melanoma. Cancers (Basel). 2023;15:1123.","journal-title":"Cancers (Basel)"},{"key":"2749_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-020-00912-3","volume":"13","author":"X Xiao","year":"2020","unstructured":"Xiao X, Liu P, Li D, Xia Z, Wang P, Zhang X, et al. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. J Hematol Oncol. 2020;13:80.","journal-title":"J Hematol Oncol"},{"key":"2749_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44270-3","volume":"15","author":"F Wang","year":"2024","unstructured":"Wang F, Li Y, Yang Z, Cao W, Liu Y, Zhao L, et al. Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Nat Commun. 2024;15:203.","journal-title":"Nat Commun"},{"key":"2749_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70\u20138.","journal-title":"J Immunol Methods"},{"key":"2749_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom Bioinforma. 2022;20:587\u201396.","journal-title":"Genomics Proteom Bioinforma"},{"key":"2749_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401142","volume":"11","author":"K Qian","year":"2024","unstructured":"Qian K, Li W, Ren S, Peng W, Qing B, Liu X, et al. HDAC8 Enhances the Function of HIF-2\u03b1 by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCC. Adv Sci (Weinh). 2024;11:e2401142.","journal-title":"Adv Sci (Weinh)"},{"key":"2749_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43519-1","volume":"14","author":"MF Emmons","year":"2023","unstructured":"Emmons MF, Bennett RL, Riva A, Gupta K, Carvalho L, Zhang C, et al. HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis. Nat Commun. 2023;14:7759.","journal-title":"Nat Commun"},{"key":"2749_CR39","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","volume":"79","author":"MF Emmons","year":"2019","unstructured":"Emmons MF, Fai\u00e3o-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res. 2019;79:2947\u201361.","journal-title":"Cancer Res"},{"key":"2749_CR40","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1182\/blood-2012-07-441022","volume":"121","author":"T Higuchi","year":"2013","unstructured":"Higuchi T, Nakayama T, Arao T, Nishio K, Yoshie O. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia\/lymphoma. Blood. 2013;121:3640\u20139.","journal-title":"Blood"},{"key":"2749_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-022-00265-2","volume":"11","author":"T Shi","year":"2022","unstructured":"Shi T, Xie M, Chen L, Yuan W, Wang Y, Huang X, et al. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era. Exp Hematol Oncol. 2022;11:13.","journal-title":"Exp Hematol Oncol"},{"key":"2749_CR42","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrc2468","volume":"8","author":"NC Denko","year":"2008","unstructured":"Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705\u201313.","journal-title":"Nat Rev Cancer"},{"key":"2749_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1756-9966-31-28","volume":"31","author":"ZJ Dai","year":"2012","unstructured":"Dai ZJ, Gao J, Ma XB, Yan K, Liu XX, Kang HF, et al. Up-regulation of hypoxia inducible factor-1\u03b1 by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells. J Exp Clin Cancer Res. 2012;31:28.","journal-title":"J Exp Clin Cancer Res"},{"key":"2749_CR44","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/sj.leu.2404408","volume":"20","author":"C Picard","year":"2006","unstructured":"Picard C, Hayette S, Bilhou-Nabera C, Cayuela JM, Delabesse E, Frenoy N, et al. Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. Leukemia. 2006;20:2178\u201381.","journal-title":"Leukemia"},{"key":"2749_CR45","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5:e618\u2013e27.","journal-title":"Lancet Haematol"},{"key":"2749_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","volume":"133","author":"F Ravandi","year":"2019","unstructured":"Ravandi F. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2019;133:130\u20136.","journal-title":"Blood"},{"key":"2749_CR47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"S Soverini","year":"2014","unstructured":"Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120:1002\u20139.","journal-title":"Cancer"},{"key":"2749_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399\u2013401.","journal-title":"Science"},{"key":"2749_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/sj.leu.2404554","volume":"21","author":"DW Sherbenou","year":"2007","unstructured":"Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 2007;21:489\u201393.","journal-title":"Leukemia"},{"key":"2749_CR50","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood.2022018196","volume":"142","author":"S Qiu","year":"2023","unstructured":"Qiu S, Sheth V, Yan C, Liu J, Chacko BK, Li H, et al. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells. Blood. 2023;142:574\u201388.","journal-title":"Blood"},{"key":"2749_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02162-0","volume":"23","author":"C Zeng","year":"2024","unstructured":"Zeng C, Nie D, Wang X, Zhong S, Zeng X, Liu X, et al. Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+\u2009leukemia stem cells. Mol Cancer. 2024;23:240.","journal-title":"Mol Cancer"},{"key":"2749_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110752","volume":"39","author":"V Morris","year":"2022","unstructured":"Morris V, Wang D, Li Z, Marion W, Hughes T, Sousa P, et al. Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Cell Rep. 2022;39:110752.","journal-title":"Cell Rep"},{"key":"2749_CR53","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","volume":"130","author":"G Cheloni","year":"2017","unstructured":"Cheloni G, Tanturli M, Tusa I, Ho DeSouza N, Shan Y, Gozzini A, et al. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood. 2017;130:655\u201365.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02749-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02749-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02749-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:03:44Z","timestamp":1762337024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02749-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2749"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02749-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}